A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II study is designed to investigate the efficacy and safety of BL-B01D1 monotherapy, SI-B003 monotherapy, and BL-B01D1+SI-B003 combination therapy in patients with extensive-stage small cell lung cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 18 do 75 lat
- •Potwierdzony zaawansowany rak płuca drobnowarkowego
- •Spodziewany czas przeżycia co najmniej 3 miesiące
- •Ogólny stan zdrowia pozwalający na leczenie (ECOG 0-1)
- •Co najmniej jeden widoczny guz możliwy do zmierzenia
- •Prawidłowe wyniki funkcji wątroby, nerek i badań krwi
- •Chęć dostarczenia próbki tkanki guza do badania
- •Dobrowolna zgoda na udział w badaniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- August 27, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Jilin Cancer Hospital
Changchun, China
Trial contact
Sa Xiao, PHD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/28/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.